Rigel Pharmaceuticals
RIGL
125 hedge funds and large institutions have $260M invested in Rigel Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 18 closing their positions.
48,650% more call options, than puts
Call options by funds: $975K | Put options by funds: $2K
22% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 36
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
2% more funds holding
Funds holding: 123 → 125 (+2)
4% more capital invested
Capital invested by funds: $250M → $260M (+$9.94M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 77.88% → 77.72% (-0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.98M |
| 2 |
Goldman Sachs
New York
|
+$2.33M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$2.18M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$1.81M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$8.96M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.36M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$2.16M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$2.03M |
| 5 |
BlackRock
New York
|
-$2.03M |
RIGL Hedge Fund Activity: Q2 2025 in Review
125 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2025, worth a combined $260M — up 4% from $250M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RIGL positions and 18 closed out — a net gain of 2 holders — while 44 added to existing stakes and 36 trimmed.
The largest buyer was Marshall Wace, adding an estimated $2.98M. The largest seller was Soleus Capital Management, cutting an estimated $8.96M.
- 125 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2025, up from 123 in Q1 2025.
- Funds reported $260M of Rigel Pharmaceuticals stock for Q2 2025, up 4% quarter-over-quarter.
- 20 funds opened new Rigel Pharmaceuticals positions in Q2 2025 and 18 closed out, a net change of +2 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2025 was Marshall Wace, an estimated $2.98M added.
- The largest Rigel Pharmaceuticals seller in Q2 2025 was Soleus Capital Management, an estimated $8.96M sold.
Based on aggregated 13F filings for Q2 2025.